TABLE 1.
Sensitivity and specificity of baseline cytology, genotyping and ASCL1/LHX8 methylation for detection of CIN3+ and CIN2+
| Sensitivity | Specificity | PPV | NPV | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n/N | % | 95% CI | n/N | % | 95% CI | % | 95% CI | % | 95% CI | |
| (A) Cytology | ||||||||||
| CIN3+ | 81/91 | 89.0% | (82.6‐95.4%) | 389/624 | 62.3% | (58.5‐66.1%) | 25.6% | (20.8‐30.4%) | 97.5% | (96.0‐99.0%) |
| CIN2+ | 138/163 | 84.7% | (79.1‐90.2%) | 374/552 | 67.8% | (63.9‐71.7%) | 43.7% | (38.2‐49.1%) | 93.7% | (91.4‐96.1%) |
| (B) HPV16/18 genotyping | ||||||||||
| CIN3+ | 61/83 | 73.5% | (64.0‐83.0%) | 383/567 | 67.5% | (63.7‐71.4%) | 24.9% | (19.5‐30.3%) | 94.6% | (92.4‐96.8%) |
| CIN2+ | 76/146 | 68.7% | (51.6‐67.5%) | 346/504 | 68.7% | (64.6‐72.7%) | 35.5% | (29.5‐41.5%) | 85.4% | (82.0‐88.9%) |
| (C) ASCL1/LHX8 methylation a | ||||||||||
| CIN3+ | 70/91 | 76.9% | (68.3‐85.6%) | 465/624 | 74.5% | (71.1‐77.9%) | 30.6% | (24.6‐36.5%) | 95.7% | (93.9‐97.5%) |
| CIN2+ | 97/163 | 59.5% | (52.0‐67.0%) | 420/552 | 76.1% | (72.5‐79.6%) | 42.4% | (36.0‐48.8%) | 86.4% | (83.4‐89.5%) |
| (D) Cytology + HPV16/18 genotyping | ||||||||||
| CIN3+ | 79/83 | 95.2% | (90.6‐99.8%) | 248/567 | 43.7% | (39.7‐47.8%) | 19.8% | (15.9‐23.8%) | 98.4% | (96.9‐100.0%) |
| CIN2+ | 130/146 | 89.0% | (84.0‐94.1%) | 236/504 | 46.8% | (42.5‐51.2%) | 32.7% | (28.1‐37.3%) | 93.7% | (90.6‐96.7%) |
| (E) ASCL1/LHX8 methylation a + HPV16/18 genotyping | ||||||||||
| CIN3+ | 72/83 | 86.7% | (79.5‐94.0%) | 302/567 | 53.3% | (49.2‐57.4%) | 21.4% | (17.0‐25.7%) | 96.5% | (94.4‐98.5%) |
| CIN2+ | 112/146 | 76.7% | (69.9‐83.6%) | 279/504 | 55.4% | (51.0‐59.7%) | 33.2% | (28.2‐38.3%) | 89.1% | (85.7‐92.6%) |
Abbreviations: CI, confidence interval; CIN, cervical intraepithelial neoplasia; n, number of; N, group size; NPV, negative predicted value; PPV, positive predicted value.
a
Using a predefined threshold (70% specificity).